Transcenta Holding Limited — Capital/Financing Update 2021

Oct 18, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [138 x 40] intentionally omitted <==

Transcenta Holding Limited 創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

VOLUNTARY ANNOUNCEMENT ACQUISITION OF LAND USE RIGHT

This announcement is made by Transcenta Holding Limited (the “ Company ”) on a voluntary basis to inform the shareholders and potential investors of the Company about its latest business development.

Reference is made to the prospectus of the Company dated September 14, 2021 (the “ Prospectus ”) in relation to the Company’s plan of constructing a new continuous perfusion and fed-batch hybrid plant in Suzhou Industrial Park. Capitalized terms used herein but no otherwise defined shall have the same meaning ascribed thereto in the Prospectus.

The board of directors of the Company (the “ Board ”) is pleased to announce that MabSpace Biosciences (Suzhou) Co., Ltd. (邁博斯生物醫藥（蘇州）有限公司) (“ MabSpace Biosciences ”), a wholly-owned subsidiary of the Company, recently made a successful online bid for the transfer of state-owned construction land use right of a parcel of land located in Suzhou Industrial Park, Jiangsu Province, the People’s Republic of China (the “ PRC ”) with code no. 320513102208GB88209 (the “ Land Parcel ”) through public listing and tender held by Suzhou Industrial Park Planning and Construction Committee* (蘇州工業園區規劃建設委員會) (the “ Vendor ”) and entered into a contract with the Vendor in relation to the formal acquisition of the Land Parcel on October 11, 2021 (the “ Acquisition ”), for a total consideration of RMB17.04 million (the “ Consideration ”). MabSpace Biosciences obtained the real estate certificate (不動產 權證書) of the Land Parcel on October 14, 2021.

The Consideration will be financed by the internal resources and bank borrowings of the Group. To the best of the Directors’ knowledge, information and belief and having made all reasonable enquiries, the Vendor and its ultimate beneficial owner are third parties independent of the Group and its connected persons.

The Land Parcel is situated at west of Qingqiu Street, north of Zhongyuan Road* (青丘街西、鍾 園路北), Suzhou Industrial Park, Jiangsu Province, the PRC with a total site area of approximately 46,174.26 square meters and permitted plot ratio of between 2.5 and 3.0. The Land Parcel is designated for industrial usage with the term of use of 30 years.

1

The Company is a clinical stage biopharmaceutical company that integrates the capacities of discovery, research, development, manufacturing and business development. The principal business activity of MabSpace Biosciences is research, development, manufacturing and commercialization of pharmaceutical drug candidates and provision of related technical services.

The Company intends to use the Land Parcel to construct a new manufacturing facility to support the expanding needs of the existing and upcoming pipeline. The new facility will utilize the Company’s Integrated Continuous Bioprocessing (ICB) Platform to develop and produce clinical trial materials and commercial products, support the launch of approved products for global markets. While the new facility is designed based on the principal of continuous biomanufacturing for drug substance production, it can also handle the traditional fed-batch based process. The new facility will also feature high-speed commercial fill and finish drug product lines. In view of the location and designated use of the Land Parcel, the Board considers that the Acquisition is in line with the business development strategies and plans of the Company, and is on normal commercial terms which are fair and reasonable and in the interests of the Company and its shareholders as a whole.

As all applicable percentage ratios (as defined in Rule 14.07 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “ Listing Rules ”)) of the Acquisition do not exceed 5%, the Acquisition does not constitute a notifiable transaction under Chapter 14 of the Listing Rules.

By Order of the Board Transcenta Holding Limited Xueming Qian Executive Director and Chief Executive Officer

Hong Kong, October 18, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director and chief executive officer, Dr. Michael Ming Shi and Mr. Albert Da Zhu as executive Directors, Dr. Yining (Jonathan) Zhao as chairman and non-executive Director, and Mr. Jiasong Tang, Dr. Jun Bao and Mr. Zhihua Zhang as independent non-executive Directors.

• For identification purpose only

2